Prenetics / DNAFit Acquire Oxsed (Oxford University Spin-out)
October 28, 2020
Hong Kong-based Prenetics, via its UK entity DNAFit Life Sciences Limited, has acquired Oxsed, an Oxford University spin-out that developed a rapid RT-LAMP COVID-19 testing platform. The acquisition gives DNAFit/Prenetics exclusive global rights to the Oxsed technology to accelerate R&D, scale manufacturing and deploy rapid point-of-care testing (including airport trials) worldwide.
- Buyers
- DNAFit Life Sciences Limited, Prenetics Limited
- Targets
- Oxsed
- Industry
- Medical Devices
- Location
- England, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
QuidelOrtho Acquires LEX Diagnostics to Expand Ultra-Fast Point-of-Care PCR
April 20, 2026
Healthcare Services
QuidelOrtho Corporation completed the acquisition of LEX Diagnostics for approximately $100 million in cash. The deal adds the LEX VELO System, an ultra-fast molecular (multiplex RT-PCR) platform designed to deliver results for Influenza A, Influenza B, and COVID-19 in about six to ten minutes from a swab.
-
Embecta Acquires Owen Mumford Holdings for Up to £150 Million
March 27, 2026
Healthcare Services
Embecta entered into a definitive agreement to acquire Owen Mumford Holdings Limited for up to £150 million, consisting of £100 million upfront cash and up to £50 million in performance-based payments tied to net sales of the Aidaptus next-generation auto-injector platform. The deal was designed to accelerate embecta’s transformation into a broader medical supplies company with a differentiated drug-delivery platform for pharmaceutical partners and chronic care patients across obesity, diabetes, autoimmune diseases, and anaphylaxis.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
WuXi AppTec Completes Acquisition of OXGENE
March 2, 2021
Biotechnology
WuXi AppTec, via its cell and gene therapy unit WuXi Advanced Therapies (WuXi ATU), completed the acquisition of Oxford-based OXGENE on March 2, 2021. The purchase brings OXGENE's gene-therapy discovery and viral-vector manufacturing technologies into WuXi ATU, expanding its capabilities and establishing its first European facility to better serve global cell and gene therapy customers.
-
P4 Diagnostix Acquires Assets of Strand Diagnostics (know error)
February 11, 2020
Healthcare Services
P4 Diagnostix announced the acquisition of the assets of Strand Diagnostics, the creator of the know error DNA specimen provenance testing system. P4 said it will resume testing, supplies and logistics for know error clients and immediately offer Strand's UroSeq assay to expand P4's molecular testing capabilities for urology and oncology customers.
-
Eurofins Scientific Acquires Majority Stake in LifeCodexx
July 27, 2017
Biotechnology
Eurofins Scientific has acquired a 62.63% stake in LifeCodexx AG from GATC Biotech AG, strengthening Eurofins' non-invasive prenatal testing (NIPT) capabilities. LifeCodexx, headquartered in Constance, Germany, is a developer of the PrenaTest NIPT and generated approximately EUR 7m in revenue in 2016.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.